Oxford Handbook of Clinical Haematology, Second Edition

Total Page:16

File Type:pdf, Size:1020Kb

Oxford Handbook of Clinical Haematology, Second Edition Oxford Handbook of Clinical Haematology, Second edition Drew Provan, et al. OXFORD UNIVERSITY PRESS 00-Prelims i-viii 10.12.2003 03.51 PM Page i Oxford Handbook of Clinical Haematology 00-Prelims i-viii 10.12.2003 03.51 PM Page ii Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to- date published product information and data sheets provided by the manu- facturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. ᮣ Except where otherwise stated (e.g. Paediatric Haematology), drug doses and recommendations are for the non-pregnant adult who is not breast-feeding. 00-Prelims i-viii 10.12.2003 03.51 PM Page iii Oxford Handbook of Clinical Haematology Second edition Drew Provan Senior Lecturer in Haematology, Barts and The London, Queen Mary’s School of Medicine and Dentistry, University of London Charles R. J. Singer Consultant Haematologist, Royal United Hospital, Bath, UK Trevor Baglin Consultant Haematologist, Addenbrookes NHS Trust, Cambridge, UK John Lilleyman Professor of Paediatric Oncology & Consultant Paediatric Haematologist, Barts and The London, Queen Mary’s School of Medicine and Dentistry, University of London 1 00-Prelims i-viii 10.12.2003 03.51 PM Page iv 1 Great Clarendon Street, Oxford OX2 6DP Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide in Oxford New York Auckland Bangkok Buenos Aires Cape Town Chennai Dar es Salaam Delhi Hong Kong Istanbul Karachi Kolkata Kuala Lumpur Madrid Melbourne Mexico City Mumbai Nairobi São Paulo Shanghai Taipei Tokyo Toronto Oxford is a trade mark of Oxford University Press Published in the United States by Oxford University Press, Inc., New York © Oxford University Press 2004 The moral rights of the author have been asserted Database right Oxford University Press (maker) First edition published 1998 Reprinted 1999, 2000, 2003 Second edition published 2004 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above. This book is sold subject to the condition that it shall not, by way of trade or otherwise, be lent, re-sold, hired out, or otherwise circulated without the publisher’s prior consent in any form of binding or cover other than that in which it is published and without a similar condition including this condition being imposed on the subsequent purchaser. British Library Cataloguing in Publication Data Data available 1 3 5 7 9 10 8 6 4 2 ISBN 0 19 852652 0 Typeset by Drew Provan and EXPO, Malaysia Printed by 00-Prelims i-viii 10.12.2003 03.51 PM Page v Foreword to the first edition The Concise Oxford Dictionary defines a handbook as ‘a short manual or guide’. Modern haematology is a vast field which involves almost every other medical speciality and which, more than most, straddles the worlds of the basic biomedical sciences and clinical practice. Since the rapidly pro- liferating numbers of textbooks on this topic are becoming denser and heavier with each new edition, the medical student and young doctor in training are presented with a daunting problem, particularly as they try to put these fields into perspective. And those who try to teach them are not much better placed; on the one hand they are being told to decongest the curriculum, while on the other they are expected to introduce large slices of molecular biology, social science, ethics and communication skills, not to mention a liberal sprinkling of poetry, music and art. In this over-heated educational scene the much maligned ‘handbook’ could well stage a come-back and gain new respectability, particularly in the role of a friendly guide. In the past this genre has often been viewed as having little intellectual standing, of no use to anybody except the panic- stricken student who wishes to try to make up for months of mis-spent time in a vain, one-night sitting before their final examination. But given the plethora of rapidly changing information that has to be assimilated, the carefully prepared précis is likely to play an increasingly important role in medical education. Perhaps even that ruination of the decent paragraph and linchpin of the pronouncements of medical bureaucrats, the ‘bullet- point’, may become acceptable, albeit in small doses, as attempts are made to highlight what is really important in a scientific or clinical field of enormous complexity and not a little uncertainty. In this short account of blood diseases the editors have done an excel- lent service to medical students, as well as doctors who are not specialists in blood diseases, by summarising in simple terms the major features and approaches to diagnosis and management of most of the blood diseases that they will meet in routine clinical practice or in the tedious examina- tions that face them. And in condensing this rapidly expanding field they have, remarkably, managed to avoid one of the great difficulties and pitfalls of this type of teaching; in trying to reduce complex issues down to their bare bones, it is all too easy to introduce inaccuracies. One word of warning from a battle-scarred clinician however. A précis of this type suffers from the same problem as a set of multiple-choice questions. Human beings are enormously complex organisms, and sick ones are even more complicated; during a clinical lifetime the self-critical doctor will probably never encounter a ‘typical case’ of anything. Thus the outlines of the diseases that are presented in this book must be used as approximate guides, and no more. But provided they bear this in mind, students will find that it is a very valuable summary of modern haema- tology; the addition of the Internet sources is a genuine and timely bonus. D. J. WEATHERALL April 1998 00-Prelims i-viii 10.12.2003 03.51 PM Page vi Preface to the second edition Haematology has seen many changes since 1998 when the first edition of this small book was written. Most notably, there are major advances in the treatments of malignant blood disorders with the discovery of tyrosine kinase inhibitors which have transformed the outlook for patients with CML, the rediscovery of arsenic for AML and many other new therapies. Progress has been slower in the non-malignant arena since there is still limited evidence on which to base decisions. We have attempted to update each section in the book in order to ensure that it reflects current practice. Although molecular diagnostics have seen huge changes through the Human Genome Project and other methodological developments, we have not included these in great detail here because of lack of space. We have attempted to focus more on clinical aspects of patient care. This edition welcomes two new authors: Professor Sir John Lilleyman, immediate Past-President of the Royal College of Pathologists, is a Paediatric Oncologist at Barts and The London, Queen Mary’s School of Medicine and Dentistry, University of London. John is a leading figure in the world of paediatric haematology with an interest in both malignant and non-malignant disease affecting children. He has extensively revised the Paediatric section of the book, in addition to Immunodeficiency. Dr Trevor Baglin, Consultant Haematologist at Addenbrookes Hospital, Cambridge is Secretary of the British Committee for Standards in Haematology Haemostasis and Thrombosis Task Force. Trevor is the author of many evidence-based guidelines and peer-reviewed scientific papers. He has rewritten the Haemostasis section of the book and brought this in line with modern management. Other features of this edition include the greater use of illustrations such as blood films, marrows and radiological images which we hope will enhance the text and improve readers’ understanding of the subject. We have increased the number of references and provided URLs for key web- sites providing easy access to organisations and publications. There will doubtless be omissions and errors and we take full responsi- bility for these. We are very keen to receive feedback (good or other- wise!) since this helps shape future editions. If there is something you feel we have left out please complete the Readers comment card. DP CRJS TB JL January 2004 00-Prelims i-viii 10.12.2003 03.51 PM Page vii Preface to the first edition This small volume is intended to provide the essential core knowledge required to assess patients with possible disorders of the blood, organise relevant investigations and initiate therapy where necessary. By reducing extraneous information as much as possible, and presenting key informa- tion for each topic, a basic understanding of the pathophysiology is pro- vided and this, we hope, will stimulate readers to follow this up by consulting the larger haematology textbooks. We have provided both a patient-centred and disease-centred approach to haematological disease, in an attempt to provide a form of ‘surgical sieve’, hopefully enabling doctors in training to formulate a differ- ential diagnosis before consulting the relevant disease-orientated section. We have provided a full review of haematological investigations and their interpretation, handling emergency situations, and included the com- monly used protocols in current use on Haematology Units, hopefully providing a unified approach to patient management.
Recommended publications
  • Mcqs and Emqs in Surgery
    1 The metabolic response to injury Multiple choice questions ➜ Homeostasis B Every endocrine gland plays an equal 1. Which of the following statements part. about homeostasis are false? C They produce a model of several phases. A It is defined as a stable state of the D The phases occur over several days. normal body. E They help in the process of repair. B The central nervous system, heart, lungs, ➜ kidneys and spleen are the essential The recovery process organs that maintain homeostasis at a 4. With regard to the recovery process, normal level. identify the statements that are true. C Elective surgery should cause little A All tissues are catabolic, resulting in repair disturbance to homeostasis. at an equal pace. D Emergency surgery should cause little B Catabolism results in muscle wasting. disturbance to homeostasis. C There is alteration in muscle protein E Return to normal homeostasis after breakdown. an operation would depend upon the D Hyperalimentation helps in recovery. presence of co-morbid conditions. E There is insulin resistance. ➜ Stress response ➜ Optimal perioperative care 2. In stress response, which of the 5. Which of the following statements are following statements are false? true for optimal perioperative care? A It is graded. A Volume loss should be promptly treated B Metabolism and nitrogen excretion are by large intravenous (IV) infusions of related to the degree of stress. fluid. C In such a situation there are B Hypothermia and pain are to be avoided. physiological, metabolic and C Starvation needs to be combated. immunological changes. D Avoid immobility. D The changes cannot be modified.
    [Show full text]
  • The Differential Diagnosis of Bone Marrow Edema on Wrist MRI
    Skeletal Radiology (2019) 48:1525–1539 https://doi.org/10.1007/s00256-019-03204-1 REVIEW ARTICLE Review article: the differential diagnosis of bone marrow edema on wrist MRI WanYin Lim1,2 & Asif Saifuddin3,4 Received: 5 December 2018 /Revised: 1 February 2019 /Accepted: 5 March 2019 /Published online: 22 March 2019 # ISS 2019 Abstract There is a large variety of conditions that can result in ‘bone marrow edema’ or ‘bone marrow lesions’ (BML) in the wrist on magnetic resonance imaging (MRI). The combination of clinical history and the distribution of the BML can serve as a valuable clue to a specific diagnosis. This article illustrates the different patterns of BML in the wrist to serve as a useful guide when reviewing wrist MRI studies. Imaging artefacts will also be briefly covered. Keywords MRI . Wrist . Marrow edema . Bone marrow lesion Introduction The etiology of BMLs can also be confusing due to the non-specific appearance, MRI demonstrating poorly defined Bone marrow lesions (BML), or marrow signal reduced T1-weighted spin echo (T1W SE) marrow signal in- hyperintensity on fluid-sensitive magnetic resonance im- tensity (SI) (Fig. 1a) with corresponding hyperintensity on aging (MRI) sequences, are observed in up to 36% of short tau inversion recovery (STIR), fat-suppressed T2W fast patients undergoing wrist MRI [1]. With regard to def- spin echo (FS T2W FSE), and fat-suppressed proton density- inition, the term ‘bone marrow lesion’ (BML) used in weighted fast spin echo (FS PDW FSE) sequences (Fig. 1b). this manuscript is synonymous with ‘edema-like marrow There may also be overlapping patterns between different en- signal’, ‘marrow edema-like signal’ or ‘bone marrow tities, but the combination of clinical history and lesion loca- edema pattern’ [2].
    [Show full text]
  • Clinicopathological Case: Progressive Somnolence and Dementia in an Accountant
    Clinicopathological case: progressive somnolence and dementia in an accountant Authors Tim Soane 1, Jonathan M Schott 2, Jon Stone 1, Colin Smith 3, Suvankar Pal 4, Richard J Davenport 1 1. Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK 2. Dementia Research Centre, University College London Institute of Neurology, London, UK 3. Department of Neuropathology, Western General Hospital, Edinburgh, UK 4. Forth Valley Royal Hospital, Larbert, UK Correspondence to: Dr Tim Soane, Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK; [email protected] Abstract A 63-year-old accountant developed progressive somnolence, cognitive decline, gait disturbance and cerebellar dysfunction with autonomic features. This report documents the clinicopathological conference at the 39th Edinburgh Advanced Neurology Course 2017. History A 63-year-old right-handed accountant became unwell in summer 2013, with abdominal symptoms, somnolence, unsteadiness and weight loss of two stones. He had stopped driving due to safety concerns; he had become withdrawn, lost enjoyment playing guitar, had reduced libido and had become reluctant to leave the house. He was taking omeprazole and fluoxetine. He had previously undergone mastoid surgery. He lived with his wife and daughter, had never smoked and drank little alcohol. He had completed a 400-mile bike trip in India in 2011 (Figure 1A). His mother and maternal grandmother had dementia in their 80s. Initial examination showed square wave jerks, unsteady gait and finger-nose ataxia, worse on the left. An Addenbrooke’s Cognitive Examination-Revised (ACE-R) score was 99/100. He was diagnosed with sleep apnoea, and initially responded well to continuous positive airway pressure (CPAP), but by mid-2015 was sleeping up to 20 hours/day.
    [Show full text]
  • MINAX Contains the Active Ingredient Metoprolol Tartrate CONSUMER MEDICINE INFORMATION
    MINAX contains the active ingredient metoprolol tartrate CONSUMER MEDICINE INFORMATION What is in this leaflet blood vessels in the body, as well as lung problems, or have had helping the heart to beat more them in the past This leaflet answers some common regularly. • You have a history of allergic questions about MINAX. It does not Your doctor will have explained why problems, including hayfever contain all of the available you are being treated with MINAX • You have low blood pressure information. and told you what dose to take. MINAX may be used either alone or • You have a very slow heartbeat It does not take the place of talking to (less than 45-50 beats/minute) your doctor or pharmacist. in combination with other medicines to treat your condition. • You have certain other heart All medicines have benefits and conditions risks. Your doctor has weighed the Ask your doctor if you have any risks of you taking MINAX against questions about why MINAX has • You have phaeochromocytoma the benefits they expect it will have been prescribed for you. (a rare tumour of the adrenal for you. Your doctor may have prescribed gland) which is not being MINAX for another reason. treated already with other If you have any concerns about medicines taking this medicine, talk to your Follow all directions given to you • You have a severe blood vessel doctor or pharmacist. by your doctor carefully. disorder causing poor Keep this leaflet with your They may differ from the circulation in the arms and legs medicine. information contained in this leaflet.
    [Show full text]
  • CORONARY ARTERY DISEASE Etiology and Pathophysiology
    806 Section 7 Problems of Oxygenation: Perfusion ing can be injured as a result of tobacco use, hyperlipidemia, hy- 493,623 pertension, diabetes, hyperhomocysteinemia, and infection (e.g., 500 433,825 Males Chlamydia pneumoniae, herpes) causing a local infl ammatory re- sponse3,4 (Fig. 34-2, A). 400 Females C-reactive protein (CRP), a nonspecifi c marker of infl amma- tion, is increased in many patients with CAD. Chronic exposure to 300 288,768 268,503 even minor elevations of CRP can trigger the rupture of plaques Cardiovascular System Cardiovascular and promote the oxidation of low-density lipoprotein (LDL) cho- 200 lesterol, leading to increased uptake by macrophages in the endo- 5,6 64,103 thelial lining. Deaths in thousands 69,257 41,877 100 60,713 Developmental Stages. CAD is a progressive disease that 34,301 38,948 takes many years to develop. When it becomes symptomatic, the 0 disease process is usually well advanced. The stages of development ABCDE ABDEF in atherosclerosis are (1) fatty streak, (2) fi brous plaque resulting from smooth muscle cell proliferation, and (3) complicated lesion. A Total CVD (Preliminary) D Chronic Lower Respiratory Diseases B Cancer E Diabetes Mellitus Fatty Streak. Fatty streaks, the earliest lesions of atherosclero- 2 C Accidents F Alzheimer’s Disease sis, are characterized by lipid-fi lled smooth muscle cells. As streaks of fat develop within the smooth muscle cells, a yellow FIG. 34-1 Leading causes of death for all men and women. CVD, Cardiovas- cular disease. tinge appears. Fatty streaks can be observed in the coronary arter- ies by age 15 and involve an increasing amount of surface area as the patient ages.
    [Show full text]
  • Disease Processes and Diagnostic Techniques 1
    Disease processes and diagnostic techniques 1 1. Surgery and the mechanisms of surgical disease 3 DISEASE PROCESSES 2. Managing physiological change in the surgical patient 9 3. Immunity, infl ammation and infection 27 4. Shock and resuscitation 52 DIAGNOSTIC TECHNIQUES 5. Imaging and interventional techniques in surgery 59 6. Screening for adult disease 88 CCh001-F10345.inddh001-F10345.indd 1 55/7/2007/7/2007 44:05:47:05:47 PPMM CCh001-F10345.inddh001-F10345.indd 2 55/7/2007/7/2007 44:05:47:05:47 PPMM Surgery and the mechanisms of surgical disease 1 A SHORT HISTORY OF SURGERY ................................................ 3 PRINCIPAL MECHANISMS OF SURGICAL DISEASE .................... 5 Congenital conditions ..................................................................................... 5 APPROACHES TO SURGICAL PROBLEMS ................................... 4 Acquired conditions ......................................................................................... 6 A SHORT HISTORY OF SURGERY There can be no doubt that the fi rst surgeons were the The fi rst scientifi c departure from this barbaric treat- men and women who bound up the lacerations, contu- ment was taken by the great French military surgeon sions, fractures, impalements and eviscerations to which Ambroise Paré (1510–1590) who, while still a young man, man has been subject since he appeared on Earth. Since revolutionised the treatment of wounds by using only man is the most vicious of all creatures, many of these simple dressings, abandoning cautery and introducing injuries were infl icted by man upon man. Indeed, the ligatures to control haemorrhage. He established that his battlefi eld has always been a training ground for surgery. results were much better than could be achieved by the Right up to the 15th century, surgeons dealing with old methods.
    [Show full text]
  • METOPROLOL IV MYLAN Metoprolol Tartrate
    METOPROLOL IV MYLAN metoprolol tartrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about METOPROLOL IV MYLAN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given METOPROLOL IV MYLAN against the benefits they expect it will have for you. If you have any concerns about being given this medicine, ask your doctor, nurse or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What METOPROLOL IV MYLAN is used for Your medicine contains metoprolol tartrate as the active ingredient. This medicine belongs to a group of medicines called beta-blockers. METOPROLOL IV MYLAN 1 Metoprolol tartrate is used to treat an irregular heartbeat, also known as arrhythmia, which means that there is a disturbance of the heart's normal rhythm or beat. Arrhythmias may be caused by numerous factors, including some heart diseases, an overactive thyroid gland or chemical imbalances. After a heart attack there is also a chance of developing an arrhythmia. Metoprolol tartrate helps to restore your heart beat to a more normal rate, particularly if it is beating very fast. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason. This medicine is not addictive. Before you are given METOPROLOL IV MYLAN When you must not be given it You should not be given METOPROLOL IV MYLAN if: • you have any allergies to metoprolol tartrate, any other beta-blocker medicine, any of the ingredients listed at the end of this leaflet.
    [Show full text]
  • Retinal Image Analysis and Diagnosis of Retinal Blood Vascular Diseases Using Deep Learning Model
    Retinal Image Analysis and Diagnosis of Retinal Blood Vascular Diseases using Deep Learning Model Bismita Choudhury (Student ID: 100063702) A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) (Computer Science and Engineering) Faculty of Engineering, Computing, and Science Swinburne University of Technology Sarawak Campus May/2019 “Research is what I’m doing when I don’t know what I’m doing.” – Wernher von Braun THESIS – DOCTOR OF PHILOSOPHY (PHD) Abstract The retina is not only an important part of the visual system, but it also has the potential to indicate the general health of the other parts of the human body. In addition to the eye disease, various retinal abnormalities can be indicative of other health issues. Recent studies have show n that these retinal abnormalities associated with the blood vascular disease are predictive to several major diseases, viz., Diabetes, Cardiovascular diseases like Hypertension and Coronary heart disease, Kidney disease, and Stroke. Among the various blood vascular diseases, Diabetic Retinopathy (DR) and Retinal Vein Occlusion (RVO) are the two leading causes of blindness worldwide. The main causes for both of these sight-threatening retinal diseases are the age, obesity and sedentary lifestyle of people. As these factors are beyond controllable to avoid such diseases, therefore, it is particularly important to detect these retinal abnormalities as early as possible and prevent the visual imparity. The recent years have seen the increased interest in diagnosing various diseases through Computer Aided Diagnosis (CAD) of the digital images. In past decades, several such methods have been proposed for diagnosing DR.
    [Show full text]
  • Clinical Research on the Rehabilitation of Stroke Patients' Motor Ability
    2002. Vol. 3. No. 1. 107-119 Korean Journal of Oriental Medicine Original Article Clinical Research on the rehabilitation of Stroke patients’ motor ability Chang-Nam Ko, Sang-Kwan Moon, Ki-Ho Cho, Young-Suk Kim, Hyung-Sub Bae, Kyung-Sub Lee Department of Cardiovascular and Neurological diseases(Storke center) Kyunghee University, Seoul, Korea Abstract Background and Purpose: This clinical study investigated the effect of oriental medical treatment (herbal medicine, acupuncture & moxibustion therapy, physiotherapy, etc.) for the motor recovery improvement in stroke patients. The MBI (Modified Barthel Index) and NIHSS (National Institute of Health Stroke Scale) were used to evaluate the motor recovery in these patients. Methods: We selected the 151 stroke patients (79 male and 72 female) who visited Kang Nam Korean Hospital, Kyunghee University from June 1. 2000 to June 30. 2001 and investigated their characteristics, risk factors, past history, lesion area and size, symptoms, admission period and the period from onset to admission. We analyzed the MBI & NIHSS records to prove the efficacy of oriental medical treatment. Results and conclusions: Age distribution shows in 60s, 70s, 50s, 40s and 80s. The average age was 65.6±10.0. Gender ratio was 1.09:1(M:F). Lesion areas were mostly in the MCA (Middle Cerebral Artery), multifocal, brainstem and PCA (Posterior Cerebral Artery). Antecedent diseases of stroke patients were hypertension (78.4%), heart diseases, and diabetes mellitus, prior attacks. Symptoms of these patients are motor disturbance, verbal disturbance, swallowing disturbance and stool and urine disturbance. The mean admission period was 35.3±36.2 days. The significant period from onset to admission was 23.6 ±42.8 days.
    [Show full text]
  • BETALOC® TABLETS Metoprolol Tartrate
    BETALOC® TABLETS Metoprolol tartrate Consumer Medicine Information What is in this leaflet the heart has to do. It also widens the hives on the skin or you may feel blood vessels in the body, as well as faint. This leaflet answers some of the helping the heart to beat more • you have asthma, wheezing, common questions people ask about regularly. difficulty breathing or other BETALOC tablets. It does not Your doctor will have explained why lung problems, or have had contain all the information that is you are being treated with them in the past known about BETALOC. BETALOC and told you what dose • you have a history of allergic It does not take the place of talking to to take. problems, including hayfever your doctor or pharmacist. BETALOC may be used either alone • you have low blood pressure All medicines have risks and or in combination with other medicines to treat your condition. • you have a very slow heartbeat benefits. Your doctor will have (less than 45-50 beats/minute) weighed the risks of you taking Ask your doctor if you have any BETALOC against the benefits they questions about why BETALOC • you have certain other heart expect it will have for you. has been prescribed for you. conditions If you have any concerns about Your doctor may have prescribed this • you have phaeochromocytoma taking this medicine, ask your medicine for another reason. (a rare tumour of the adrenal doctor or pharmacist. gland) which is not being Follow all directions given to you treated already with other Keep this leaflet with the medicine.
    [Show full text]
  • Rare and Hereditary Causes of Stroke-A Literature Review Eyisi CS1*, Onwuekwe IO1, Eyisi IG2 and Ekenze O1
    Eyisi et al. Int J Neurodegener Dis 2018, 1:005 Volume 1 | Issue 1 Open Access International Journal of Neurodegenerative Disorders RESEARCH ARTICLE Rare and Hereditary Causes of Stroke-A Literature Review Eyisi CS1*, Onwuekwe IO1, Eyisi IG2 and Ekenze O1 1Neurology Unit, Department of Medicine, College of Medicine, University of Nigeria Teaching Hospital, Nigeria Check for 2Department of Community Medicine, College of Medicine, Chukwuemeka Odumegwu Ojukwu University, updates Nigeria *Corresponding author: Dr. Eyisi Chioma, Neurology Unit, Department of Medicine, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State, Nigeria, Tel: +2348168858498 brainstem stroke syndromes and herniation syndromes. Abstract Background: Rare and hereditary diseases are important Traditionally stokes are classified as ischemic or hem- in causing stroke in children, younger patients and women orrhagic, the former more common than the latter in a [1]. These diseases have a world-wide prevalence, howev- ratio of 6:1 [1]. Conventional risk factors for stroke oc- er they are not commonly diagnosed in Nigeria because of currence have also be described and grouped into mod- unavailability of gene mapping technologies. Notable ex- ceptions include Moyamoya disease which commonly occur ifiable and non-modifiable risk factors [1]. Modifiable in Asian populations and Chronic Myelogenous Leukemia risk factors include hypertension, Smoking, Lifestyle, Al- which causes stroke in the 7th and 8th decade, in contrast to cohol, High cholesterol, Atrial fibrillation, Obesity, Dia- other diseases that cause stroke in the 1st to 3rd decades [1]. betes, Severe carotid stenosis, Sleep apnea. Non-modi- Aim: The aim of this paper is to review several rare and fiable risk factors comprise of Male sex, African race and hereditary causes of stroke.
    [Show full text]
  • Sandoz Bisoprolol Tablets Con
    READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Sandoz Bisoprolol Tablets Bisoprolol fumarate 5 mg, 10 mg tablets Read this carefully before you start taking Sandoz Bisoprolol Tablets and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about Sandoz Bisoprolol Tablets. What is Sandoz Bisoprolol Tablets used for? Sandoz Bisoprolol Tablets is used to treat hypertension (high blood pressure). How does Sandoz Bisoprolol Tablets work? Bisoprolol belongs to the group of drugs called "beta-blockers". Sandoz Bisoprolol Tablets decreases blood pressure and reduces how hard the heart has to work. What are the ingredients in Sandoz Bisoprolol Tablets? Medicinal ingredients: Bisoprolol fumarate Non-medicinal ingredients: calcium hydrogen phosphate, colloidal anhydrous silica, croscarmellose sodium, hypromellose, lactose monohydrate, macrogol (polyethylene glycol), maize starch (pregelatinised), magnesium stearate, microcrystalline cellulose, red ferric oxide (10 mg only), titanium dioxide and yellow ferric oxide (5 mg and 10 mg only). Sandoz Bisoprolol Tablets comes in the following dosage forms: 5 mg, 10 mg tablets Do not use Sandoz Bisoprolol Tablets if you: are allergic to bisoprolol, any of the non-medicinal ingredients or to another beta- blocker; have severe drops in blood pressure, dizziness, fast heartbeat, rapid and shallow breathing, cold clammy skin (signs of a heart disorder called cardiogenic shock); have a slow or irregular heartbeat or have been told you have heart block; have heart failure and your symptoms are getting worse.
    [Show full text]